KLC1 and central nervous system cancer: The inhibition of JAK-STAT signaling successfully suppressed the oncogenic properties of KLC1-ROS1 fusion-expressing human glioma cells, suggesting that JAK-STAT signaling could be a novel therapeutic target against KLC1-ROS1 fusion-positive gliomas.